In a filing, KalVista Pharmaceuticals Inc revealed its CHIEF SCIENTIFIC OFFICER Feener Edward P. unloaded Company’s shares for reported $0.4 million on Feb 20 ’24. In the deal valued at $14.07 per share,28,288 shares were sold. As a result of this transaction, Feener Edward P. now holds 62,157 shares worth roughly $0.74 million.
Then, Crockett Thomas Andrew sold 24,888 shares, generating $351,289 in total proceeds. Upon selling the shares at $14.11, the CEO now owns 211,203 shares.
Before that, Palleiko Benjamin L sold 22,802 shares. KalVista Pharmaceuticals Inc shares valued at $321,846 were divested by the CFO, CBO at a price of $14.11 per share. As a result of the transaction, Palleiko Benjamin L now holds 187,315 shares, worth roughly $2.23 million.
H.C. Wainwright initiated its KalVista Pharmaceuticals Inc [KALV] rating to a Buy in a research note published on June 15, 2020; the price target was $30. A number of analysts have revised their coverage, including SVB Leerink’s analysts, who began to cover the stock in late July with a ‘”an Outperform”‘ rating. Needham began covering KALV with “Buy” recommendation on March 20, 2019. Jefferies started covering the stock on October 30, 2018. It rated KALV as “a Buy”.
Price Performance Review of KALV
On Tuesday, KalVista Pharmaceuticals Inc [NASDAQ:KALV] saw its stock jump 1.19% to $11.88. Over the last five days, the stock has gained 0.59%. KalVista Pharmaceuticals Inc shares have fallen nearly -3.02% since the year began. Nevertheless, the stocks have risen 50.19% over the past one year. While a 52-week high of $16.88 was reached on 02/01/24, a 52-week low of $7.21 was recorded on 03/26/24. SMA at 50 days reached $12.98, while 200 days put it at $10.89. A total of 0.49 million shares were traded, compared to the trading of 0.31 million shares in the previous session.
Levels Of Support And Resistance For KALV Stock
The 24-hour chart illustrates a support level at 11.51, which if violated will result in even more drops to 11.14. On the upside, there is a resistance level at 12.21. A further resistance level may holdings at 12.54. The Relative Strength Index (RSI) on the 14-day chart is 48.33, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.31, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 34.97%. Stochastics %K at 64.02% indicates the stock is a holding.
The most recent change occurred on September 21, 2018 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating.
